Effects of GSK 1521498 on neural and behavioural responses in obese patients with moderate binge eating

Trial Profile

Effects of GSK 1521498 on neural and behavioural responses in obese patients with moderate binge eating

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2013

At a glance

  • Drugs GSK 1521498 (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top